The intertwining of the two strands of a DNA helix poses a number of topological problems by catalyzing changes in DNA topology through a concerted mechanism of DNA strand breakage and rejoining. This process is accompanied by the formation of covalent enzyme-DNA intermediates, which conserve the energy of the broken phosphodiester linkages. A number of therapeutically important drugs, including the potent antineoplastic agent camptothecin, reversibly stabilize these covalent complexes. Camptothecin specifically targets eukaryotic DNA topoisomerase 1, which is highly conserved in terms of its primary amino acid sequence, mechanism of action and drug sensitivity. The cytotoxicity of camptothecin is S-phase dependent, resulting from the double-strand DNA breaks produced by the collision of DNA replication forks with the drug-stabilized enzyme-DNA adducts. However, little is known about the mechanisms involved in the processing and repair of these potentially lethal lesions, or the signaling pathways required for drug- induced cell killing. This application proposes to define the pathway of camptothecin-induced cell lethality, by screening for yeast and human gene products whose overexpression in the yeast Saccharomyces cerevisiae protects these cells from drug-mediated cell death. Since the phenotypic consequences of camptothecin treatment are faithfully reiterated in yeast, the cellular processes involved in converting the drug-stabilized complexes into lethal lesions can be experimentally addressed in this genetically tractable system. The subsequent identification of these high copy suppressor (HCS) genes and their cellular functions, both in yeast and in mammalian cells, will elucidate athe cellular processes required for camptothecin-induced DNA damage and apoptosis. The ability of these genes to suppress related mechanisms of cell death will also be examined in yeast and mammalian cells expressing lethal DNA topoisomerase 1 mutants that mimic the cytotoxic action of camptothecin. These studies will further our understanding of the mechanism of drug-induced lethality, and will also lead to greater understanding of how normal cellular functions can be perturbed to a cause cell death. As several camptothecin analogs have been entered into clinical trials for the treatment of ovarian, breast, colon and non small cell lung cancers, the characterization of HCS gene functions will have much broader applications in the design and development of new therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA070406-04
Application #
2871890
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
1996-04-01
Project End
2000-01-31
Budget Start
1999-04-26
Budget End
2000-01-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Fiorani, Paola; Reid, Robert J D; Schepis, Antonino et al. (2004) The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons. J Biol Chem 279:21271-81
Bjornsti, Mary Ann (2002) Cancer therapeutics in yeast. Cancer Cell 2:267-73
Woo, Michael H; Vance, John R; Marcos, Ana R Otero et al. (2002) Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. J Biol Chem 277:3813-22
Woo, M H; Vance, J R; Bjornsti, M A (2001) Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae. Methods Mol Biol 95:303-13
Fiorani, P; Bjornsti, M A (2000) Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Ann N Y Acad Sci 922:65-75
Bjornsti, M A; Fertala, J (1999) Overexpression and purification of DNA topoisomerase I from yeast. Methods Mol Biol 94:179-86
Fiorani, P; Amatruda, J F; Silvestri, A et al. (1999) Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Mol Pharmacol 56:1105-15
Bjornsti, M A; Osheroff, N (1999) Introduction to DNA topoisomerases. Methods Mol Biol 94:1-8
Reid, R J; Fiorani, P; Sugawara, M et al. (1999) CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc Natl Acad Sci U S A 96:11440-5
Kang, J J; Schaber, M D; Srinivasula, S M et al. (1999) Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae. J Biol Chem 274:3189-98

Showing the most recent 10 out of 12 publications